ClinicalTrials.gg
CompletedNCT04672499Updated Dec 17, 2020

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

A Phase 1 interventional study of Miricorilant 300 mg tablets and Miricorilant 150 mg tablets in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2020, 6 years 2 months ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Apr 2020, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) of miricorilant (CORT118335) tablet formulations following single and multiple oral administration in healthy participants.

Read the detailed description

Cohort 1 will evaluate safety, tolerability, and PK of single doses of a 150-mg and a new 300-mg tablet formulation of miricorilant. Cohort 1 treatment will be randomized and open label.

Optional Cohorts 2 and 3 will evaluate single- and repeated-dose administration of miricorilant using a formulation, dose, and dose-regimen determined after interim evaluation of PK and safety data from previous cohorts. Cohort 2 and 3 treatments will be randomized, blinded, and placebo controlled.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18.0 to 30.0 kg/m\^2
  • Must agree to adhere to the requirements
  • Additional criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Received any medicinal product in a clinical research study within the last 90 days
  • Male participants who have pregnant or lactating partners
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption: a confirmed positive alcohol breath test at screening or admission
  • Current smokers and those who have smoked or used e-cigarettes or nicotine replacement products within the last 6 months
  • Females of including those who are pregnant or lactating (all female subjects must have a negative serum pregnancy test at screening and a negative urine pregnancy test at admission)
  • abnormal clinical chemistry, haematology or urinalysis as judged by the Investigator
  • Confirmed positive drugs of abuse test result
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
  • Active renal and/or hepatic disease
  • History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, chronic respiratory, neurological or psychiatric disorder, as judged by the Investigator
  • Any form of cancer within the last 2 years (exceptions apply)
  • History and/or symptoms of adrenal insufficiency
  • Regularly consumes liquorice or other glycyrrhetic acid derivatives
  • History of clinically significant gastrointestinal disease
  • Currently using or have a history of systemic glucocorticoid use within the last 12 months or 3 months for inhaled products
  • Presence or history of clinically significant allergy requiring treatment
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Taking, or have taken, any prescribed, over-the-counter drug (other than up to 4 g per day paracetamol) or vitamins/herbal remedies within 14 days. Exceptions may apply on a case by case basis
  • Additional criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1: Miricorilant 900 mg (Regimen A1)

    Participants will receive a single oral dose of miricorilant 900 mg (3 X 300 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.

    Drug: Miricorilant 300 mg tablets

  • Experimental
    Cohort 1: Miricorilant 300 mg (Regimen A2)

    Participants will receive a single oral dose of miricorilant 300 mg (2 X 150 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.

    Drug: Miricorilant 150 mg tablets

  • Experimental
    Cohort 2: Miricorilant (Regimen B1 and B2)

    Participants will receive a single oral dose of miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.

    Drug: Miricorilant 150 mg tablets

  • Placebo comparator
    Cohort 2: Placebo (Regimen B1 and B2)

    Participants will receive a single oral dose of placebo matching miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.

    Drug: Placebo 150 mg tablets

  • Experimental
    Cohort 3: Miricorilant (Regimen C1 and C2)

    Participants will receive two oral doses (morning and evening) of miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.

    Drug: Miricorilant 150 mg tablets

  • Placebo comparator
    Cohort 3: Placebo (Regimen C1 and C2)

    Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.

    Drug: Placebo 150 mg tablets

Interventions

  • Miricorilant 300 mg tablets for oral administration

    Also known as: CORT118335

  • Miricorilant 150 mg tablets for oral administration

    Also known as: CORT118335

  • DrugPlacebo 150 mg tablets

    Placebo to match miricorilant 150 mg tablets for oral administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with One or More Adverse Events

    Time frame: Up to 7±2 days after the last dose (up to approximately Day 9 for Cohort 1 and up to approximately Day 23 for Cohorts 2 and 3)

  2. Percentage of Participants with One or More Serious Adverse Events

    Time frame: Up to 7±2 days after the last dose (up to approximately Day 9 for Cohort 1 and up to approximately Day 23 for Cohorts 2 and 3)

  3. Percentage of Participants Discontinued from the Study due to an Adverse Event

    Time frame: Up to 7±2 days after the last dose (up to approximately Day 9 for Cohort 1 and up to approximately Day 23 for Cohorts 2 and 3)

Secondary outcomes

  1. Plasma Pharmacokinetics (PK) of Miricorilant: Elapsed Time from Dosing at which the Analyte was First Quantifiable in a Concentration vs Time Profile (tlag)

    Time frame: Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4)

  2. Plasma PK of Miricorilant: Maximum Observed Concentration (Cmax)

    Time frame: Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4); Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)

  3. Plasma PK of Miricorilant: Time from Dosing at which Cmax was Apparent (Tmax)

    Time frame: Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4); Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)

  4. Plasma PK of Miricorilant: Apparent Elimination Half-life (t1/2)

    Time frame: Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4); Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)

  5. Plasma PK of Miricorilant: Area Under the Curve from Time Zero to the Last Measurable Concentration (AUC0-last)

    Time frame: Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4)

  6. Plasma PK of Miricorilant: Area Under the Curve from Time Zero to 24 Hours Postdose (AUC0-24)

    Time frame: Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Sep 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2020
First posted
Dec 17, 2020
StartActual
Apr 27, 2020
Primary completionActual
Sep 7, 2020
CompletionActual
Sep 7, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04672499
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Apr 27, 2020
Primary completion
Sep 7, 2020
Completion
Sep 7, 2020
Last update
Dec 17, 2020

Study contacts

Sharan Sidhu, MBChB, BAO, MRCS, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion